DR. PATRICK L. GOMEZ MD NPI 1972640134

NPI Details

DR. Patrick L. Gomez, MD is a hematology and oncology internal medicine in Bloomington, IL with 43 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Patrick L. Gomez, MD NPI is 1972640134. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: DUKE UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1983

The provider's business location address is:

3105 MAGORY DR
BLOOMINGTON, IL
ZIP 61704-403
Phone: (309) 243-3000

The NPI 1972640134 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron binding capacity (HCPCS:83550)
• Iron level (HCPCS:83540)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Folic acid level, serum (HCPCS:82746)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Magnesium level (HCPCS:83735)
• Ct scan of chest with contrast (HCPCS:71260)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection of drug or substance into vein (HCPCS:96374)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Red blood count, automated test (HCPCS:85045)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Protein measurement, serum (HCPCS:84165)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Electrophoresis, laboratory testing technique (HCPCS:82664)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Uric acid level, blood (HCPCS:84550)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Unclassified drugs (HCPCS:J3490)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Phosphate level (HCPCS:84100)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Bilirubin level, direct (HCPCS:82248)
• Ct scan of chest without contrast (HCPCS:71250)
• Vitamin d-3 level (HCPCS:82306)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 1/30/2007 and was last updated on 9/30/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.